ACXP Acurx Pharmaceuticals, Inc.
Fundamentals / CIK 0001736243 / USDAcurx Pharmaceuticals, Inc. reported $10.34M in total assets and a net loss of $8.10M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ACXP in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-$8.27M Operating profit
-
Net Income FY 2025-$8.10M GAAP bottom line
-
Diluted EPS FY 2025-$1.52 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$9.65M Total debt: --
Annual revenue and net income
6 fiscal years (2020 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Research & Development | $1.83M | $5.40M | $6.04M | $4.75M | $2.03M | $2.20M |
| Selling, General & Admin | -- | -- | -- | -- | $208K | -- |
| Total Operating Expenses | $8.09M | $14.12M | $14.58M | $12.09M | $12.81M | $4.60M |
| Operating Income | -$8.09M | -$14.12M | -- | -- | -- | -- |
| Interest Income | $125K | $20K | -- | -- | -- | -- |
| Income Tax Expense | -- | -- | -- | $0 | -- | $0 |
| Net Income | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M | -$4.60M |
| Basic EPS | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| Diluted EPS | -$5.32 | -$17.45 | -$23.00 | -$22.40 | -$29.80 | -$14.80 |
| Basic Shares Outstanding | 1.5M | 808.2K | 633.6K | 540.8K | 426.8K | 309.5K |
| Diluted Shares Outstanding | 1.5M | 808.2K | 633.6K | 540.8K | 426.8K | 309.5K |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $1.12M | $1.07M | $341K | $282K | $430K | $524K | $599K | $825K |
| Total Operating Expenses | $2.63M | $2.31M | $1.72M | $1.62M | $2.03M | $2.27M | $2.18M | $2.79M |
| Operating Income | -$2.63M | -$2.31M | -$1.72M | -$1.62M | -$2.03M | -$2.27M | -$2.18M | -- |
| Interest Income | $48K | $53K | $35K | $39K | $36K | $23K | $27K | -- |
| Net Income | -$2.58M | -$2.25M | -$1.68M | -$1.58M | -$1.99M | -$2.25M | -$2.15M | -$2.78M |
| Basic EPS | -$0.49 | -$0.53 | -$0.62 | -- | -$1.23 | -$1.89 | -$2.15 | -- |
| Diluted EPS | -$0.49 | -$0.53 | -$0.62 | -- | -$1.23 | -$1.89 | -$2.15 | -- |
| Basic Shares Outstanding | 5.3M | 4.3M | 2.7M | -- | 1.6M | 1.2M | 1.0M | -- |
| Diluted Shares Outstanding | 5.3M | 4.3M | 2.7M | -- | 1.6M | 1.2M | 1.0M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $7.56M | $3.71M | $7.47M | $9.11M | $12.96M | $3.18M |
| Cash & Short-Term Investments | $7.56M | $3.71M | $7.47M | $9.11M | $12.96M | $3.18M |
| Total Current Assets | -- | $3.86M | $7.71M | $9.38M | $13.25M | -- |
| Total Non-Current Assets | -- | $0 | $0 | $0 | $0 | -- |
| Total Assets | $7.69M | $3.86M | $7.71M | $9.38M | $13.25M | $3.22M |
| Total Current Liabilities | $2.42M | $3.24M | $3.04M | $2.06M | $844K | $473K |
| Total Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $50K |
| Total Liabilities | $2.42M | $3.24M | $3.04M | $2.06M | $844K | $522K |
| Common Stock | $2.3K | $852 | $14K | $12K | $10K | -- |
| Retained Earnings | -$75.29M | -$67.32M | -$53.22M | -$38.64M | -$26.55M | -$13.80M |
| Total Stockholders' Equity | $5.27M | $615K | $4.67M | $7.32M | $12.41M | $2.70M |
| Total Equity | $5.27M | $615K | $4.67M | $7.32M | $12.41M | $2.70M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $9.65M | $10.66M | $9.25M | $7.56M | $5.91M | $3.71M | $6.36M | $8.92M |
| Cash & Short-Term Investments | $9.65M | $10.66M | $9.25M | $7.56M | $5.91M | $3.71M | $6.36M | $8.92M |
| Total Current Assets | -- | -- | -- | -- | -- | $3.86M | -- | -- |
| Total Non-Current Assets | -- | -- | -- | -- | -- | $0 | -- | -- |
| Total Assets | $10.34M | $10.98M | $9.54M | $7.69M | $6.11M | $3.86M | $6.58M | $9.11M |
| Total Current Liabilities | $2.99M | $2.83M | $2.53M | $2.42M | $2.47M | $3.24M | $3.15M | $3.11M |
| Total Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.99M | $2.83M | $2.53M | $2.42M | $2.47M | $3.24M | $3.15M | $3.11M |
| Common Stock | $5.9K | $4.7K | $3.4K | $2.3K | $1.8K | $852 | $16K | $16K |
| Retained Earnings | -$81.81M | -$79.22M | -$76.97M | -$75.29M | -$73.71M | -$67.32M | -$61.72M | -$57.60M |
| Total Stockholders' Equity | $7.34M | $8.15M | $7.01M | $5.27M | $3.64M | $615K | $3.43M | $6.00M |
| Total Equity | $7.34M | $8.15M | $7.01M | $5.27M | $3.64M | $615K | $3.43M | $6.00M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Net Income | -$7.97M | -$14.10M | -$14.58M | -$12.09M | -$12.75M | -$4.60M |
| Stock-Based Compensation | $1.25M | $2.60M | $3.21M | $2.87M | $5.15M | $696K |
| Operating Cash Flow | -$6.79M | -$10.38M | -$9.80M | -$7.54M | -$5.01M | -$3.35M |
| Common Stock Issued | -- | -- | -- | $3.70M | -- | -- |
| Financing Cash Flow | $10.64M | $6.62M | $8.16M | $3.70M | $14.80M | $4.04M |
| Net Change in Cash | $3.85M | -$3.77M | -$1.64M | -$3.85M | $9.78M | $692K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.58M | -$2.25M | -$1.68M | -$1.58M | -$1.99M | -$2.25M | -$2.15M | -$2.78M |
| Stock-Based Compensation | $208K | $201K | $258K | $295K | $295K | $324K | $334K | $345K |
| Operating Cash Flow | -$2.49M | -$1.71M | -$1.41M | -$1.18M | -$1.88M | -$1.67M | -$2.05M | -$2.25M |
| Financing Cash Flow | $1.49M | $3.11M | $3.11M | $2.83M | $1.72M | $3.09M | $2.99M | $195K |
| Net Change in Cash | -$1.00M | $1.40M | $1.70M | $1.65M | -$157K | $1.42M | $937K | -$2.06M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -151.2% | -2292.7% | -312.4% | -165.3% | -102.7% | -170.3% |
| Return on Assets (ROA) | -103.6% | -365.6% | -189.1% | -129.0% | -96.2% | -142.7% |
| Current Ratio | -- | 1.19x | 2.53x | 4.55x | 15.71x | -- |
| Quick Ratio | 3.12x | 1.14x | 2.46x | 4.42x | 15.36x | 6.72x |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -110.3% | -92.1% | -106.9% | -151.2% | -252.1% | -- | -- | -2292.7% |
| Return on Assets (ROA) | -78.3% | -68.3% | -78.6% | -103.6% | -150.2% | -- | -- | -365.6% |
| Current Ratio | -- | -- | -- | -- | -- | -- | -- | 1.19x |
| Quick Ratio | 3.23x | 3.76x | 3.66x | 3.12x | 2.39x | -- | -- | 1.14x |